Table 2 Treatment encounter characteristics in each year of treatment.

Number

250

13

3

4

6

8

12

9

5

11

15

10

16

21

17

17

25

35

23

First cycle (%)

40 (16)

5 (38)

0

0

1 (17)

3 (38)

4 (33)

1 (11)

2 (40)

4 (36)

3 (20)

2 (20)

2 (13)

1 (5)

0

1 (6)

5 (20)

4 (11)

2 (9)

 First line

136 (54)

9 (69)

2 (67)

2 (50)

4 (67)

7 (88)

7 (58)

7 (78)

3 (60)

10 (91)

12 (80)

7 (70)

6 (38)

12 (57)

8 (47)

5 (29)

9 (36)

15 (43)

11 (48)

 Second line

29 (12)

4 (31)

1 (33)

1 (25)

2 (33)

1 (13)

2 (17)

1 (11)

1 (20)

0

3 (20)

1 (10)

2 (13)

2 (10)

0

1 (6)

2 (8)

3 (9)

2 (9)

 Third line

5 (2)

0

0

0

0

0

0

0

0

0

0

0

1 (6)

1 (5)

1 (6)

0

1 (4)

1 (3)

0

 Maintenance

80 (32)

0

0

1 (25)

0

0

3 (25)

1 (11)

1 (20)

1 (9)

0

2 (20)

9 (44)

6 (29)

8 (47)

11 (65)

13 (52)

16 (46)

10 (43)

Type of SACT (%)

 Single-agent chemotherapy

50 (20)

6 (46)

2 (67)

2 (50)

1 (17)

1 (13)

4 (33)

1 (11)

2 (40)

2 (18)

1 (7)

4 (40)

7 (44)

3 (14)

2 (12)

4 (24)

5 (20)

2 (6)

1 (4)

 Platinum-based doublet

83 (33)

5 (46)

1 (33)

2 (50)

4 (67)

7 (88)

7 (58)

6 (67)

2 (40)

8 (73)

11 (73)

5 (50)

2 (12)

6 (29)

4 (24)

3 (18)

2 (8)

6 (17)

2 (9)

 Single agent IO

69 (28)

0

0

0

0

0

0

0

0

0

3 (20)

1 (10)

7 (44)

12 (57)

11 (65)

10 (59)

6 (24)

7 (20)

12 (52)

 Chemotherapy & IO

40 (16)

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

12 (48)

20 (57)

8 (35)

 Other

8 (3)

2 (15)

0

0

1 (17)

0

1 (8)

2 (22)

1 (20)

1 (9)

0

0

0

0

0

0

0

0

0